Imricor Medical Systems (ASX:IMR) reported an 840% year-on-year surge to AU$255,000 in its consumables revenue for the fourth quarter of 2024, according to a Thursday filing with the Australian bourse.
Total revenue reached AU$280,000, excluding the company's first capital sale in Qatar. The sale will be recognized in future quarters upon installation, per the filing.
Cash and cash equivalents at the end of the fourth quarter stood at $15.7 million.
The medical device maker's shares rose past 3% in recent Friday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。